Advanced non-small cell lung cancer with multiple brain metastases
Conditions
Interventions
1:Combined with whole brain radiotherapy and G-CSF on the basis of immunotherapy
Sponsors
Tongji University Affiliated Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
16 Years to 35 Years
Inclusion criteria
Inclusion criteria: ? agreed to follow the trial treatment plan and visit plan, enrolled voluntarily, signed the informed consent in person, aged =18 years old, of both sexes. ? Patients with histologically or cytologically confirmed stage ? non-small cell lung cancer (according to the International Thoracic Tumor Lung Cancer Staging (IASLC) Research Manual, 8th edition) with multiple brain metastases diagnosed by brain imaging. ? The subjects had not received any treatment for brain metastases. (4) The subjects had received PD-1 inhibitor immunotherapy within 2 weeks or had not received immunotherapy. ? Measurable target lesions as judged by RECIST V1.1. ?ECOG score is 0~1; Life expectancy =12 weeks. ? Subjects must have adequate organ function. ? Fertile men and women of reproductive age were willing to use effective contraception from the time of signing the informed consent until 6 months after the last dose of the trial drug; Women of childbearing age must have a negative pregnancy test within 7 days or less before the first trial drug is administered.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the uptake rate of COVID-19 booster shot among grandparents;grandparents' intention to get a COVID-19 booster shot; | — |
Secondary
| Measure | Time frame |
|---|---|
| grandparents' attitude towards COVID-19 booster shot; | — |
Countries
China
Contacts
Public ContactXiaomei Gong
Tongji University Affiliated Pulmonary Hospital
Outcome results
None listed